News & Analysis on Clinical Trial Services & Contract Research And Development
Dispatches from DIA
Two early adopters of RBM (risk-based monitoring) – Bristol-Myers Squibb and Celgene – have provided details into the way they’re reducing clinical trial site visits to increase efficiencies around identifying risks earlier and more efficiently.
Vaccine developer Aeras and CMO (contract manufacturing organization) IDT Biologika have formed a strategic partnership that includes the acquisition of Aeras's Biopharmaceutical Development Center (BDC) manufacturing facility by IDT.
Naming drugs using active pharmaceutical ingredients (API) rather than their salts will cut down on medication and dosing errors according to the US Food and Drug Administration (FDA).
The US FDA has seized illegal medicines and medical devices sold by more than 1,050 websites.
Small-scale production techs will dominate biopharma says the UK organisation tasked with developing the £20m “biologics factory of the future” and the £38m National Biologics Manufacturing Centre in Darlington.